Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

被引：0

作者：

Qiu, Lugui ^{[1
,2
]}

Fu, Weijun ^{[3
]}

Xia, Zhongjun ^{[4
]}

Fu, Zhengzheng ^{[5
]}

Chen, Wenming ^{[6
]}

Chang, Chunkang ^{[7
]}

Fang, Baijun ^{[8
]}

An, Gang ^{[1
,2
]}

Wei, Yongqiang ^{[9
]}

Cai, Zhen ^{[10
]}

Gao, Sujun ^{[11
]}

Weng, Jianyu ^{[12
]}

Chen, Lijuan ^{[13
]}

Jing, Hongmei ^{[14
]}

Fei, Li ^{[15
]}

Liu, Zhuogang ^{[16
]}

Chen, Xiequn ^{[17
]}

Liu, Jing ^{[18
]}

Yu, Yang ^{[19
]}

Wang, Aihua ^{[19
]}

Yang, Yijun ^{[19
]}

Yu, Zhinuan ^{[19
]}

Lynch, Kevin ^{[19
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China

[3] Shanghai Chang Zheng Hosp, Dept Hematol, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China

[4] Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China

[5] Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China

[6] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China

[7] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai, Peoples R China

[8] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[9] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

[10] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Zhejiang, Peoples R China

[11] Jilin Univ, Hosp 1, Dept Hematol, Changchun, Peoples R China

[12] Guangdong Gen Hosp, Guangzhou, Peoples R China

[13] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China

[14] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[15] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[16] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

[17] Air Force Med Univ, Xijing Hosp, Xian, Peoples R China

[18] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China

[19] Antengene Therapeut Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145282

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4770

引用

页数：5

共 50 条

[41] Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex
Kambhampati, Swetha
Wong, Sandy W.
Martin, Thomas, III
Wolf, Jeffrey L.
Choudhry, Priya
Karlon, William
Wiita, Arun P.
Shah, Nina
BLOOD, 2020, 136
[42] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Ray
Wang, Jim
Masterson, Tara
Nottage, Kerri
Schecter, Jordan
Chiu, Christopher
Khokhar, Nushmia
Ahmadi, Tahamtan
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15
[43] THE MM-021 CHINA REGISTRATION TRIAL: A PHASE 2 STUDY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN CHINESE RELAPSED/REFRACTORY MYELOMA PATIENTS
Hou, J.
Du, X.
Jin, J.
Cai, Z.
Chen, F.
Zhou, D.
Yu, L.
Ke, X.
Li, X.
Wu, D.
Meng, F.
Ai, H.
Zhang, J.
Chen, N.
Mei, J.
Wang, J.
HAEMATOLOGICA, 2013, 98 : 341 - 341
[44] Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
Richardson, Paul G.
Wolf, Jeffrey Lee
Jakubowiak, Andrzej J.
Zonder, Jeffrey A.
Lonial, Sagar
Irwin, David
Densmore, John
Krishnan, Amrita
Raje, Noopur S.
Bar, Michael H.
Schlossman, Robert
Ghobrial, Irene M.
Munshi, Nikhil C.
Martin, Thomas
Laubach, Jacob P.
Allerton, Jeffrey P.
Hideshima, Teru
Sportelli, Peter
Gardner, Lesa
Anderson, Kenneth C.
BLOOD, 2011, 118 (21) : 371 - 371
[45] A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug ( IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naive to Daratumumab (dara)
Kumar, Shaji K.
Cornell, Robert F.
Landgren, Ola
Ailawadhi, Sikander
Higgins, Jack P.
Willert, Erin K.
Waltzman, Roger
Lin, Jianchang
Zhang, Yuhong
Lublinsky, Anya R.
Dash, Ajeeta B.
Hanley, Michael
Manoharan, Divya
Leichter, Morgan
Ottinger, Sean
Labotka, Richard J.
Newcomb, John
Vorog, Alexander
BLOOD, 2019, 134
[46] Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Richardson, Paul G.
Wolf, Jeff
Jakubowiak, Andrzej
Zonder, Jeff
Lonial, Sagar
Irwin, David
Densmore, John
Krishnan, Amrita
Raje, Noopur
Bar, Michael
Martin, Tom
Schlossman, Robert
Ghobrial, Irene M.
Munshi, Nikhil
Laubach, Jacob
Allerton, Jeff
Hideshima, Teru
Colson, Kathleen
Poradosu, Enrique
Gardner, Lesa
Sportelli, Peter
Anderson, Kenneth C.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4243 - 4249
[47] A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma Previously Exposed to Proteasome Inhibitors (PI) and Immunomodulatory Drugs (IMiDs)
Gasparetto, Cristina J.
Lentzsch, Suzanne
Schiller, Gary J.
Bensinger, William
Bahlis, Nizar J.
Sutherland, Heather J.
White, Darrell J.
Sebag, Michael
Kotb, Rami
Venner, Christopher P.
LeBlanc, Richard
Chen, Christine I.
Del Col, Aldo
Kauffman, Michael G.
Shacham, Sharon
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Shah, Jatin
Lipe, Brea C.
BLOOD, 2017, 130
[48] A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Richardson, Paul G.
Attal, Michel
Rajkumar, S. Vincent
San Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Corzo, Kathryn Penkus
Campana, Frank
Le-Guennec, Solenn
Dubin, Franck
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Jian Hou
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Huisheng Ai
Jingshan Zhang
Honeylet Wortman-Vayn
Nianhang Chen
Jay Mei
Jianmin Wang
Journal of Hematology & Oncology, 6
[50] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
Hou, Jian
Du, Xin
Jin, Jie
Cai, Zhen
Chen, Fangping
Zhou, Dao-bin
Yu, Li
Ke, Xiaoyan
Li, Xiao
Wu, Depei
Meng, Fanyi
Ai, Huisheng
Zhang, Jingshan
Wortman-Vayn, Honeylet
Chen, Nianhang
Mei, Jay
Wang, Jianmin
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

← 1 2 3 4 5 →